Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-04
1997-07-22
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514422, 514643, 514644, 548525, 548578, 564283, 564299, A61K 3114, A61K 3140, C07C21718, C07C21720
Patent
active
056504250
ABSTRACT:
The present disclosure relates to compounds of the general formulae: ##STR1## wherein DRUG is a steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist, and to the use of such compounds as anti-inflammatory and anti-tumor agents.
REFERENCES:
patent: 2914561 (1959-11-01), Allen et al.
patent: 2914562 (1959-11-01), Allen et al.
patent: 2914564 (1959-11-01), Allen et al.
patent: 2971001 (1961-02-01), Palopoli et al.
patent: 4536516 (1985-08-01), Harper
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4973755 (1990-11-01), Grafe
Vr. J. Pharmacol. (1993), 110, 507-517, "A current view of tamoxifen for the treatment and prevention of breast cancer", by V. Craig Jordan.
Cancer Drug Design (1986), 1, 259-268, "Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor bindning assay to N-oxides and quaternary salts", by M. Jarman, et al.
Pharmacology 1992; 45, 329-337, "Effects of Nonsteroidal Antiestrogens in the in vitro Rat Uterus", by Begona Cantabrana et al.
Neuroscience Research 4, 65-99 (1971), "Site of Action and Active Form of Local Anesthetics", Toshio Narashashi, et al.
Annals New York Academy of Sciences, "Novel Pure Antiestrogens, Mode of Action and Therapeutic Prospects", by A.E. Wakeling (1991).
Endocrin Therapies of Cancer, "Cancer Chemotherapy", by Bruce A. Chabner et al. (1990).
Reports 1477, vol. 83, No. 20, Oct. 16, 1991, "Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen", by C. Kent Osborne et al.
Endocrinology, vol. 123, No. 4, 1747-1753, "Differential Induction of Progestin-Binding Sites in Uterine Cell Types by Estrogen and Antiestrogen", by Bruce E. Ennis et al. (1988).
Eur J Cancer, vol. 29A, No. 4, 589-592, 1993, "Breast Cancer Chemoprevention", by Alberto Costa.
Annals of Medicine 25, 105-111, 1993, "Development of a Preclinical Model for Hormonal Therapy of Human Endometrial Carcinomas",by P.G. Satyaswaroop.
Academic Press Limited, Cancer Treatment Reviews (1993), 19 (Supplement B), 11-19, "Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse", by Philippa G. de Takats, et al.
Endocrinology, 1986, vol. 119, No. 6, 2261-2669, "Antiestrogen Action in the Medial Basal Hypothalamus and Pituitary of Immature Female Rats: Insights Concerning Relationships among Estrogen, Dopamine, and Prolactin", by Thomas W. Toney et al.
Journal of Endocrinology, 1991, 130, 409-414, "Pharmacological charactization of a novel oestrogen antagonist, ZK 119010, in rats and mice", by Y. Nishino et al.
Endocrinology, 1991, vol. 129, No. 3, 1568-1574, "Dose-Dependent Effects of Tamoxifen on Long Bones in Growing Rats: Influence of Ovarian Status", by Lilly Y. Moon.
Biegnon Anat
Brewster Marcus
Pharmos Corporation
Raymond Richard L.
LandOfFree
Permanently ionic derivatives of steroid hormones and their anta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Permanently ionic derivatives of steroid hormones and their anta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Permanently ionic derivatives of steroid hormones and their anta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1560241